Studies of fibrin formation and fibrinolytic function in patients with the antiphospholipid syndrome

Thrombosis Research

Volumn 133, Issue 5, 2014, Pages 936-944

  Vikerfors, Anna ^a   Svenungsson, Elisabet ^a   Ågren, Anna ^a   Mobarrez, Fariborz ^b   Bremme, Katarina ^a   Holmström, Margareta ^a   Eelde, Anna ^a   Bruzelius, Maria ^a   Elgue, Graciela ^b   Wallén, Håkan ^b   Antovic, Aleksandra ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b DANDERYD HOSPITAL   (Sweden)

Author keywords

Anticardiolipin; Antiphospholipid Syndrome; Fibrinolysis; Turbidimetry

Indexed keywords

FIBRIN;

ADULT; ANTIPHOSPHOLIPID SYNDROME; BLOOD; CASE CONTROL STUDY; FEMALE; FIBRINOLYSIS; HUMAN; MALE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; THROMBOSIS;

ADULT; ANTIPHOSPHOLIPID SYNDROME; CASE-CONTROL STUDIES; FEMALE; FIBRIN; FIBRINOLYSIS; HUMANS; MALE; MIDDLE AGED; THROMBOSIS;

EID: 84898816580     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.02.023     Document Type: Article

References (47)

1. S. Miyakis, M.D. Lockshin, T. Atsumi, D.W. Branch, R.L. Brey, and R. Cervera et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) J Thromb Haemost 4 2006 295 306
2. R. Cervera, J.C. Piette, J. Font, M.A. Khamashta, Y. Shoenfeld, and M.T. Camps et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients Arthritis Rheum 46 2002 1019 1027
3. G. Ruiz-Irastorza, M.J. Cuadrado, I. Ruiz-Arruza, R. Brey, M. Crowther, and R. Derksen et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies Lupus 20 2011 206 218
4. K. Fatah, A. Silveira, P. Tornvall, F. Karpe, M. Blomback, and A. Hamsten Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age Thromb Haemost 76 1996 535 540
5. G. Jorneskog, N. Egberg, B. Fagrell, K. Fatah, B. Hessel, and H. Johnsson et al. Altered properties of the fibrin gel structure in patients with IDDM Diabetologia 39 1996 1519 1523
6. E. Rooth, N.H. Wallen, M. Blomback, and S. He Decreased fibrin network permeability and impaired fibrinolysis in the acute and convalescent phase of ischemic stroke Thromb Res 127 2011 51 56
7. B. Kwasny-Krochin, P. Gluszko, and A. Undas Unfavorably altered fibrin clot properties in patients with active rheumatoid arthritis Thromb Res 126 2010 e11 e16
8. E. Pretorius, J. du Plooy, P. Soma, and A.Y. Gasparyan An ultrastructural analysis of platelets, erythrocytes, white blood cells, and fibrin network in systemic lupus erythematosus Rheumatol Int 2013 [Epub ahead of print]
9. J.P. Collet, J. Soria, M. Mirshahi, M. Hirsch, F.B. Dagonnet, and J. Caen et al. Dusart syndrome: a new concept of the relationship between fibrin clot architecture and fibrin clot degradability: hypofibrinolysis related to an abnormal clot structure Blood 82 1993 2462 2469
10. A. Silveira, and A. Hamsten Fibrin gel architecture influences endogenous fibrinolysis and may promote coronary artery disease Arterioscler Thromb Vasc Biol 26 2006 2419 2420
11. M.E. Carr Jr., and B.M. Alving Effect of fibrin structure on plasmin-mediated dissolution of plasma clots Blood Coagul Fibrinolysis 6 1995 567 573
12. J.P. Collet, D. Park, C. Lesty, J. Soria, C. Soria, and G. Montalescot et al. Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy Arterioscler Thromb Vasc Biol 20 2000 1354 1361
13. J.P. Collet, Y. Allali, C. Lesty, M.L. Tanguy, J. Silvain, and A. Ankri et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis Arterioscler Thromb Vasc Biol 26 2006 2567 2573
14. A.S. Wolberg Plasma and cellular contributions to fibrin network formation, structure and stability Haemophilia 16 Suppl. 3 2010 7 12
15. B. Blomback, K. Carlsson, B. Hessel, A. Liljeborg, R. Procyk, and N. Aslund Native fibrin gel networks observed by 3D microscopy, permeation and turbidity Biochim Biophys Acta 997 1989 96 110
16. M. Kalani, A. Silveira, M. Blomback, J. Apelqvist, B. Eliasson, and J.W. Eriksson et al. Beneficial effects of dalteparin on haemostatic function and local tissue oxygenation in patients with diabetes, severe vascular disease and foot ulcers Thromb Res 120 2007 653 661
17. A. Antovic, C. Perneby, G.J. Ekman, H.N. Wallen, P. Hjemdahl, and M. Blomback et al. Marked increase of fibrin gel permeability with very low dose ASA treatment Thromb Res 116 2005 509 517
18. S. Williams, K. Fatah, P. Hjemdahl, and M. Blomback Better increase in fibrin gel porosity by low dose than intermediate dose acetylsalicylic acid Eur Heart J 19 1998 1666 1672
19. S. Tehrani, F. Mobarrez, A. Antovic, P. Santesson, P.E. Lins, and U. Adamson et al. Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia Thromb Res 126 2010 e225 e231
20. M.A. Martinez-Zamora, D. Tassies, F. Carmona, G. Espinosa, R. Cervera, and J.C. Reverter et al. Thrombin activatable fibrinolysis inhibitor and clot lysis time in pregnant patients with antiphospholipid syndrome: relationship with pregnancy outcome and thrombosis Am J Reprod Immunol 62 2009 381 389
21. J.L. Curnow, M.C. Morel-Kopp, C. Roddie, M. Aboud, and C.M. Ward Reduced fibrinolysis and increased fibrin generation can be detected in hypercoagulable patients using the overall hemostatic potential assay J Thromb Haemost 5 2007 528 534
22. K.A. Krone, K.L. Allen, and K.R. McCrae Impaired fibrinolysis in the antiphospholipid syndrome Curr Rheumatol Rep 12 2010 53 57
23. M. Jurado, J.A. Paramo, M. Gutierrez-Pimentel, and E. Rocha Fibrinolytic potential and antiphospholipid antibodies in systemic lupus erythematosus and other connective tissue disorders Thromb Haemost 68 1992 516 520
24. A.M. Carter, C.M. Cymbalista, T.D. Spector, and P.J. Grant Heritability of clot formation, morphology, and lysis: the EuroCLOT study Arterioscler Thromb Vasc Biol 27 2007 2783 2789
25. E.M. Tan, A.S. Cohen, J.F. Fries, A.T. Masi, D.J. McShane, and N.F. Rothfield et al. The 1982 revised criteria for the classification of systemic lupus erythematosus Arthritis Rheum 25 1982 1271 1277
26. S. He, H. Cao, A. Antovic, and M. Blomback Modifications of flow measurement to determine fibrin gel permeability and the preliminary use in research and clinical materials Blood Coagul Fibrinolysis 16 2005 61 67
27. M.E. Carr Jr., L.L. Shen, and J. Hermans Mass-length ratio of fibrin fibers from gel permeation and light scattering Biopolymers 16 1977 1 15
28. A. Antovic, G. Jorneskog, and N.H. Wallen Comparison of two laboratory assays for the investigation of fibrin gel porosity Thromb Haemost 98 2007 1386 1388
29. M. Pieters, N. Covic, T. Loots du, F.H. van der Westhuizen, D.G. van Zyl, and P. Rheeder et al. The effect of glycaemic control on fibrin network structure of type 2 diabetic subjects Thromb Haemost 96 2006 623 629
30. S. Dey A new rapid air-drying technique for scanning electron microscopy using tetramethylsilane: application to mammalian tissue Cytobios 73 1993 17 23
31. A. Vikerfors, F. Mobarrez, K. Bremme, M. Holmstrom, A. Agren, and A. Eelde et al. Studies of microparticles in patients with the antiphospholipid syndrome (APS) Lupus 21 2012 802 805
32. V. Pengo, A. Ruffatti, C. Legnani, P. Gresele, D. Barcellona, and N. Erba et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome J Thromb Haemost 8 2010 237 242
33. P. de Pablo, A. Ramirez, E. Cortina, A. de la Pena, J. Zamora, and R. Izaguirre et al. Increased fibrin polymerization rate in patients with primary antiphospholipid syndrome and systemic lupus erythematosus Clin Appl Thromb Hemost 9 2003 221 225
34. P.R. Ames, L. Iannaccone, J.D. Alves, A. Margarita, L.R. Lopez, and V. Brancaccio Factor XIII in primary antiphospholipid syndrome J Rheumatol 32 2005 1058 1062
35. P. Siljander, O. Carpen, and R. Lassila Platelet-derived microparticles associate with fibrin during thrombosis Blood 87 1996 4651 4663
36. M. Galli, D. Luciani, G. Bertolini, and T. Barbui Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature Blood 101 2003 1827 1832
37. M. Galli, G. Borrelli, E.M. Jacobsen, R.M. Marfisi, G. Finazzi, and R. Marchioli et al. Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study Blood 110 2007 1178 1183
38. A. Vikerfors, A.B. Johansson, J.T. Gustafsson, A. Jonsen, D. Leonard, and A. Zickert et al. Clinical manifestations and anti-phospholipid antibodies in 712 patients with systemic lupus erythematosus: evaluation of two diagnostic assays Rheumatology (Oxford) 52 2013 501 509
39. T. Mehrani, and M. Petri IgM anti-beta2 glycoprotein I is protective against lupus nephritis and renal damage in systemic lupus erythematosus J Rheumatol 38 2011 450 453
40. J.E. Salmon, and P.G. de Groot Pathogenic role of antiphospholipid antibodies Lupus 17 2008 405 411
41. M.H. Rosove, and P.M. Brewer Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients Ann Intern Med 117 1992 303 308
42. E. Svenungsson, J. Gustafsson, D. Leonard, J. Sandling, I. Gunnarsson, and G. Nordmark et al. A STAT4 risk allele is associated with ischaemic cerebrovascular events and anti-phospholipid antibodies in systemic lupus erythematosus Ann Rheum Dis 69 2010 834 840
43. E. Lundstrom, J.T. Gustafsson, A. Jonsen, D. Leonard, A. Zickert, and K. Elvin et al. HLA-DRB1*04/*13 alleles are associated with vascular disease and antiphospholipid antibodies in systemic lupus erythematosus Ann Rheum Dis 72 2013 1018 1025
44. A.H. Guimaraes, E.L. de Bruijne, T. Lisman, D.W. Dippel, J.W. Deckers, and D. Poldermans et al. Hypofibrinolysis is a risk factor for arterial thrombosis at young age Br J Haematol 145 2009 115 120
45. M. Blomback, S. He, N. Bark, H.N. Wallen, and M. Elg Effects on fibrin network porosity of anticoagulants with different modes of action and reversal by activated coagulation factor concentrate Br J Haematol 152 2011 758 765
46. A. Tripodi Testing for lupus anticoagulants: all that a clinician should know Lupus 18 2009 291 298
47. V. Regnault, S. Beguin, D. Wahl, E. de Maistre, H. Coenraad Hemker, and T. Lecompte Thrombinography shows acquired resistance to activated protein C in patients with lupus anticoagulants Thromb Haemost 89 2003 208 212